Trending...
- John Robert Powers Alum Dakota Johnson Stars in Verity, in Theaters October 2
- Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
- Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
NORTHFIELD, Ill. ~ NORTHFIELD, Ill.-- The College of American Pathologists (CAP) has recently released an updated version of their "Principles of Analytic Validation of Immunohistochemical Assays" guideline. This update aims to improve the precision and accuracy of clinical immunohistochemical assays by assessing new evidence published since the original guideline was released in 2014.
According to Jeffrey D. Goldsmith, MD, FCAP, chair of the guideline, this update is crucial as immunohistochemical assays often play a significant role in guiding therapeutic decisions for cancer treatment. The revised guideline provides new and revised recommendations for the analytic validation and verification of these assays, with a particular focus on predictive markers.
While many of the original statements from the 2014 guideline remain similar, there are several new recommendations that provide guidance for validating immunohistochemical assays performed on cytology specimens and predictive marker assays with distinct scoring systems. For initial analytic validation or verification of any assay used clinically, laboratories should aim for at least 90% overall concordance between the new assay and the comparator assay or expected results.
More on illi News
This updated guideline also applies to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2) IHC performed on breast carcinoma. These markers should also be validated at a minimum concordance rate of 90%, replacing the previously different thresholds. This recommendation aims to harmonize validation requirements for all immunohistochemical markers.
Dr. Goldsmith emphasizes that although there were no significant new findings in the systematic review conducted for this update, the numerical considerations and modeling discussed in the original document are still relevant. If unexpected results are obtained during validation or verification, it is recommended that laboratories investigate the causes with their immunohistochemistry medical director.
The updated guideline also includes a strong recommendation for predictive marker assays such as HER2 and programmed death receptor-1 (PD-L1), where more than one scoring system is used. In these cases, separate validation or verification should be performed based on the antibody clone and scoring system combination.
More on illi News
Specific guidance for validating immunohistochemistry performed on cytology specimens is also provided in the updated guideline. These recommendations are now available in an early online release in the Archives of Pathology & Laboratory Medicine and were established through the assessment of evidence published since the original guideline was released.
The CAP has made tools, resources, and information for this updated guideline available on their website, cap.org. This will help laboratories adhere to the "Principles of Analytic Validation of Immunohistochemical Assays" and ensure increased precision and accuracy of clinical immunohistochemical assays.
According to Jeffrey D. Goldsmith, MD, FCAP, chair of the guideline, this update is crucial as immunohistochemical assays often play a significant role in guiding therapeutic decisions for cancer treatment. The revised guideline provides new and revised recommendations for the analytic validation and verification of these assays, with a particular focus on predictive markers.
While many of the original statements from the 2014 guideline remain similar, there are several new recommendations that provide guidance for validating immunohistochemical assays performed on cytology specimens and predictive marker assays with distinct scoring systems. For initial analytic validation or verification of any assay used clinically, laboratories should aim for at least 90% overall concordance between the new assay and the comparator assay or expected results.
More on illi News
- Lead Smart Inc Index: 59% of Homeowner Calls Land 9am-3pm, as Google Bills Missed Calls
- SecureMaine 2026 is Here -- Thursday October 8th!
- Inkdnylon Expands Proprietary Customer, Procurement and Production Infrastructure
- Best Detailing Studio in Rockford, IL: Woks Detailing Voted Top Choice for Auto Detailing
- Chicago Story Coach Dr. Tamea Ryan Launches Story Shift Sessions to Help People Own Their Story
This updated guideline also applies to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2) IHC performed on breast carcinoma. These markers should also be validated at a minimum concordance rate of 90%, replacing the previously different thresholds. This recommendation aims to harmonize validation requirements for all immunohistochemical markers.
Dr. Goldsmith emphasizes that although there were no significant new findings in the systematic review conducted for this update, the numerical considerations and modeling discussed in the original document are still relevant. If unexpected results are obtained during validation or verification, it is recommended that laboratories investigate the causes with their immunohistochemistry medical director.
The updated guideline also includes a strong recommendation for predictive marker assays such as HER2 and programmed death receptor-1 (PD-L1), where more than one scoring system is used. In these cases, separate validation or verification should be performed based on the antibody clone and scoring system combination.
More on illi News
- Best Web Designer in Rockford, IL: N5 Studio Voted Top Choice in October 2026
- HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
- Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
- ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
- Chicago: Mayor Brandon Johnson Cuts the Ribbon on United Yards 1A, Welcoming 51 New Affordable Homes to the Back of the Yards Community
Specific guidance for validating immunohistochemistry performed on cytology specimens is also provided in the updated guideline. These recommendations are now available in an early online release in the Archives of Pathology & Laboratory Medicine and were established through the assessment of evidence published since the original guideline was released.
The CAP has made tools, resources, and information for this updated guideline available on their website, cap.org. This will help laboratories adhere to the "Principles of Analytic Validation of Immunohistochemical Assays" and ensure increased precision and accuracy of clinical immunohistochemical assays.
Filed Under: Business
0 Comments
Latest on illi News
- Indies United is pleased to present our October 2026 book releases
- Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
- NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
- Elavo Star System Introduces Innovative Approach to Professional Tree Trunk Cleaning
- OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
- Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach
- "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME
- Migguel Anggelo Celebrates the Immigrant Experience, Latino Identity, and the Power of Iconic Latin Rhythms During Hispanic Heritage Month
- John Robert Powers Alum Dakota Johnson Stars in Verity, in Theaters October 2
- Indianapolis Criminal Defense Firm Rigney Law LLC Relaunches Criminal Law Podcast "Tales from the Brown Desk"
- 3ptechies Makes Its Articles Audio-Ready With Instaread Voice Technology
- Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
- Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026
- Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
- HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
- AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
- $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
- P-Wave Classics to publish Thomas Holcroft's The Adventures of Hugh Trevor in three volumes, beginning 19 January
- Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry
- DBF Viewer 2000 v9.32 Adds New Control for Data Export